27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Our findings suggest that disease progression follows a stage-dependent MVD pattern that can identify at-risk regions. 5 key findings →
Participants: 403 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Diagnostic challenges stem from overlapping symptoms of co-occurring neurodevelopmental and psychiatric conditions, rendering standard dementia tools insufficient. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The three cognitive assessment tools were valid for detecting subjects with MCI or dementia according to ROC analysis. 5 key findings →
Design: cross-sectional Participants: 1,090 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Little is known about whether cognitive assessments can be completed remotely by older adults at risk for dementia, and there is no consensus on which tool is best. 1 key finding →
Participants: 52 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Traditional diagnostic methods for Alzheimer's disease often suffer from low accuracy and lengthy processing times, delaying crucial interventions and patient care. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Current Care and Support: Four themes emerged: Communication with empathy; Written information valuable but could be overwhelming; Referrals provided but not necessarily followed; A focus on prescribed anti-dementia medications. 5 key findings →
Design: cross-sectional Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Machine learning models consistently outperformed conventional approach. 5 key findings →
Participants: 38,746 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundDifferentiating neurodegenerative diseases can be difficult in the clinical setting. 2 key findings →
Participants: 2,751 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Serum beta-synuclein level was progressively increased in the AD continuum across the preclinical, MCI and dementia stages compared with controls and was correlated with serum pTau181 (r=0.710), NfL (r=0.494) and GFAP concentrations (r=0.621, p<0.001 for all). 5 key findings →
Participants: 56 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
BackgroundHigh blood pressure has been associated with dementia prevalence and incident. 3 key findings →
Participants: 1,435 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Diagnostic pathways for patients presenting with cognitive complaints may vary across geographies. 1 key finding →
Design: cross-sectional Participants: 6,744 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A large number of older persons are living in the community with undetected dementia. 5 key findings →
Participants: 252 Evidence: low
Full summary, score breakdown and related studies → Original source
The majority of respondents were geriatric psychiatrists (58%). 2 key findings →
Participants: 334 Evidence: low
Full summary, score breakdown and related studies → Original source
As the most prevalent form of dementia, Alzheimer's disease (AD) represents a major public health challenge. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma biomarkers were associated with comorbidities and metabolites such as estimated glomerular filtration rate, homocysteine, and high-density lipoprotein. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The maximum mean wait time under the current workflow was projected at 6.4 months, decreasing with BBM integration. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
CSF AβR better agreed with Amy-PET compared to CSF Aβ42 (Cohen's K 0.431 versus 0.05). 3 key findings →
Participants: 39 Evidence: low
Full summary, score breakdown and related studies → Original source
The clinical diagnosis of Creutzfeldt-Jakob disease (CJD) can be supported by several biochemical markers in cerebrospinal fluid (CSF) such as 14-3-3 proteins and tau protein. 4 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source
The amyloid/tau/neurodegeneration (ATN) biomarker framework has greatly progressed the diagnosis and staging of Alzheimer's disease (AD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
17 out of 33 patients were scored as FBB-PET positive. 5 key findings →
Participants: 33 Evidence: low
Full summary, score breakdown and related studies → Original source
Artificial Intelligence is a rapidly expanding field within computer science that encompasses the emulation of human intelligence by machines. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Fifty-two patients were included in this study with a median age of 77 years, of which 44% were female. 5 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source
Concomitant Alzheimer's disease (AD) pathology is a frequent event in the context of Lewy body disease (LBD), occurring in approximately half of all cases. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
When using ethnic group-specific norms, NP and functional abilities predicted diagnosis in both groups with no significant differences but BPS was only significant in Hispanics. 5 key findings →
Participants: 444 Evidence: low
Full summary, score breakdown and related studies → Original source
Among 88 African Americans with cognitive impairment (mean = 10 years follow-up), Medicare claims identified dementia <2 years from cohort diagnosis in 55%; 27% were identified 2-9.9 years after cohort diagnosis, and in 18% there was either no claims diagnosis during the study period, or claims identified dementia 10+ years after cohort diagnosis. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
10 of the 1,743 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →